3-(5-(4-methyl-cyclohexyl)-1-(2-(1,2,4)triazolo[1,5-a]pyridin-2-yl-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yl)-5-phenyl-thiophene-2-carboxylic acid | 1383384-60-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 3-(5-(4-methyl-cyclohexyl)-1-(2-(1,2,4)triazolo[1,5-a]pyridin-2-yl-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yl)-5-phenyl-thiophene-2-carboxylic acid
• 英文别名: 3-[5-(4-methylcyclohexyl)-1-[2-([1,2,4]triazolo[1,5-a]pyridin-2-yl)acetyl]-3,6-dihydro-2H-pyridin-4-yl]-5-phenylthiophene-2-carboxylic acid
• CAS: 1383384-60-8
• 化学式: C₃₁H₃₂N₄O₃S
• 分子量: 540.686
• InChiKey: XSKXQRLPJCPXPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS POLYMERASE<br/>[FR] INHIBITEURS DE LA POLYMÉRASE DU VIRUS DE L'HÉPATITE C
  申请人：COCRYSTAL DISCOVERY INC

  公开号：WO2012083105A1

  公开（公告）日：2012-06-21

  The present invention provides, among other things, compounds represented by the general Formula (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R1A, R1B, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

  本发明提供了一种由一般式（I）表示的化合物及其药用盐，其中X、Y、R1A、R1B、R2和R3如本文中的类和子类中所定义，并包括含有这种化合物的组合物（例如，药物组合物），这些化合物可用作丙型肝炎病毒聚合酶的抑制剂，因此可用作治疗HCV感染的药物。
• Inhibitors of hepatitis C virus polymerase
  申请人：COCRYSTAL DISCOVERY, INC.

  公开号：US10426762B2

  公开（公告）日：2019-10-01

  The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

  本发明除其他外，提供了通式 I 所代表的化合物：及其药学上可接受的盐，其中 X、Y、R2 和 R3 如本文类和亚类所定义，以及包含此类化合物的组合物（例如药物组合物），这些化合物可用作丙型肝炎病毒聚合酶的抑制剂，因此可用作治疗 HCV 感染的药物等。
• INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
  申请人：Lee Sam SK

  公开号：US20120183496A1

  公开（公告）日：2012-07-19

  The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R 1A , R 1B , R 2 , and R 3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
• Inhibitors of Hepatitis C Virus Polymerase
  申请人：COCRYSTAL DISCOVERY, INC.

  公开号：US20170273962A1

  公开（公告）日：2017-09-28

  The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R 2 , and R 3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
• US8771665B2
  申请人：——

  公开号：US8771665B2

  公开（公告）日：2014-07-08